Evidence & regulatory context
- Mechanism
- No confident ChEMBL match; lysophosphatidic acid (LPA) analogue/autotaxin substrate (research)
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseRadiationC57BL/6FemaleSubcutaneous (earlier work used oral and intraperitoneal)Therapeutic doses around 1 mg/kg; 10 mg/kg given without ob…From 24 h before to 72 h after irradiation
Model: Total-body irradiation (lethal dose; 6.4 to 8.6 Gy range used for dose modification factor analysis)
A single dose given between 12 h before and 26 h after lethal total-body irradiation reduced mortality by 50%, and dosing at 48 to 72 h after irradiation reduced mortality by at least 34%; dose modification factor was 1.2 using LD50/10.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.